AMRA Medical at AASLD 2022: Best-in-class MRI technology and informatics throughout the liver disease process

Linkoping, Sweden –(Business Wire) — AMRA Medical and its collaborators will present seven abstracts in the entire disease progression line in chronic liver disease, from individuals with early stage liver disease (non-alcoholic fatty liver disease; NAFLD) to cirrhosis to liver transplantation. The data presented demonstrate that frailty and sarcopenia can be assessed throughout the disease course using the same objective, accurate and precise magnetic resonance (MR)-based techniques and informatics-based image analysis. Those attending the November AASLD Liver Conference can learn more about how AMRA’s technology and informatics are used in these studies and how they support our clinical applications, AMRA® MAsS scans and AMRA® by attending an abstract presentation or visiting AMRA’s exhibit. BCP scan booth #731.

AMRA’s magnetic resonance imaging (MRI)-based technology can accurately measure various characteristics such as muscle fat infiltration, muscle volume, and fat distribution, and objectively assess muscle mass and quantity. Imaging-based technologies and unique informatics platforms that provide insights into different muscle phenotypes in different disease progression states have attracted many internal and external research groups – from researchers studying the nuances of liver disease biology to developing next-generation liver disease treatments Drug researchers and interventions. Such research has led to AMRA’s clinical products that help clinicians make care decisions for patients with liver disease.

Two abstracts involving patients with early stage liver disease and the possibility of risk stratification based on muscle composition will be presented. These include:

“Muscle composition but not liver fat predicts all-cause mortality in UK Biobank imaging study”

“Unfavorable muscle composition is an important risk factor for all-cause mortality in NAFLD”

Three abstracts – cirrhosis and two independent cohorts of liver transplant candidates – involving MR-based tests for assessing frailty and sarcopenia will be presented. These include:

“Imaging-based frailty and sarcopenia – interim results from the prospective cirrhosis cohort study ACCESS-ESLD”

“Imaging-based testing for sarcopenia — interim results from a natural history study on the liver transplant waiting list”

“Severity of muscle steatosis is associated with frailty in patients with end-stage liver disease”

Two abstracts will demonstrate the utility of AMRA’s MR-based measurements of muscle and fat in liver transplant recipients. These include:

“A randomized controlled trial of low-calorie versus low-calorie low-carbohydrate diets on metabolic phenotypes in obese liver transplant recipients​”

“The relationship between metabolic phenotype and atherogenic lipoproteins in liver transplant recipients”

Taken together, all seven abstracts (covering different cohorts in Europe and the US, ranging from early-stage chronic disease to post-liver transplant), show that AMRA’s technology is positioned to improve how researchers and clinicians stratify patients according to risk, assessing different disease stages , and to assess the impact of liver transplantation on health outcomes or the impact of other interventions after transplantation.

Eric Converse, CEO of AMRA Medical, commented: “We are proud to see that our years of research continue to help researchers develop more solutions for metabolic diseases such as liver disease. As our leader in bringing better healthcare to all As part of this ambition, AMRA is excited to see our recently FDA-approved AMRA® MAsS scan being used to support clinical care decisions for patients with cirrhosis and those undergoing liver transplantation. See this technology, along with our FDA-approved AMRA® BCP scan, which can help clinicians prevent disease by providing actionable patient insights, with real-world impact. We hope our technology and services will keep patients healthy for longer, reducing the burden on healthcare providers burden.”

Converse continued: “I hope attendees will be able to see our abstract and be part of Dr. Converse’s plenary session. Mohammad Siddiqui then visits our booth to see how all this research has led to us in surgeries like liver transplantation, cirrhosis and Amazing clinical decision support applications in chronic care such as disease prevention.”

Attend an abstract presentation or visit us at booth 731 to learn more about the application of AMRA technology in liver disease research and clinics.

Contact us or learn more about our clinical services visit our website To find information about summaries, read more here.

Source link